This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| EURACAN | |
|---|---|
| Name | EURACAN |
| Type | Non-profit network |
| Founded | 2014 |
| Headquarters | Strasbourg |
| Region served | Europe |
EURACAN
EURACAN is a European reference network for rare adult solid cancers that links clinical centres, research institutions, patient organisations and policy bodies to improve diagnosis, treatment and research for rare tumours. It coordinates multidisciplinary clinical expertise across the European Union, engages with European Commission health initiatives, interfaces with national health authorities such as Haute Autorité de Santé, and collaborates with research funders like the European Research Council and the Horizon Europe programme. EURACAN connects specialist centres to initiatives led by organisations including European Organisation for Research and Treatment of Cancer, European Society for Medical Oncology, European Cancer Organisation, World Health Organization, and patient groups such as Rare Cancers Europe.
EURACAN was established following policy developments around European Reference Networks after the Directive 2011/24/EU and the formation of networks such as ERN-EuroBloodNet and ERN-RND. Its founding involved clinical consortia from member states including centres in France, Germany, Italy, Spain, United Kingdom, Netherlands, Belgium, Sweden, Denmark, Poland and collaborations with research hubs like the Institut Gustave Roussy, Charité – Universitätsmedizin Berlin, Istituto Nazionale dei Tumori, and Hospital Clínic de Barcelona. Early milestones included alignment with initiatives driven by European Commission Horizon 2020 calls, integration with registries inspired by European Network of Cancer Registries, and engagement with advocacy by European Patients' Forum and EURORDIS.
EURACAN’s mission aligns with objectives set out by European Commission health strategies to reduce disparities in care for rare cancers such as sarcomas, neuroendocrine tumours, germ cell tumours, head and neck cancers, and hepato-pancreato-biliary cancers. Core objectives include improving access to expert consultation through mechanisms similar to the Clinical Patient Management System used by ERNs, fostering translational research with partners like the European Molecular Biology Laboratory and the European Genome-phenome Archive, and supporting clinical trials coordinated with Clinical Trials Regulation (EU) No 536/2014 frameworks. EURACAN prioritises linkages with regulatory stakeholders including the European Medicines Agency and standard-setting bodies such as Union for International Cancer Control.
EURACAN governance reflects models used by transnational networks such as European Reference Network ITHACA and European Reference Network for Rare Multisystemic Vascular Diseases. Its structure comprises a network board with representatives from accredited centres including Institut Curie, King's College Hospital, Oxford University Hospitals NHS Foundation Trust, University of Gothenburg, Azienda Ospedaliero-Universitaria di Bologna, and Sahlgrenska University Hospital. Scientific advisory groups mirror advisory panels from European Science Foundation and liaison committees with patient representation from Alveolar Capillary Dysplasia Support Group-type organisations and coalitions like Rare Cancers Europe. Operational units coordinate tumour-specific domains analogous to task forces in European Society of Surgical Oncology.
EURACAN organises tumour-specific clinical networks covering sarcomas, central nervous system tumours, endocrine tumours, thoracic cancers, digestive rare cancers, and dermatologic oncology, inspired by domain models from European Lung Foundation and European Neuro-Oncology Society. Research areas include genomics partnerships with Wellcome Trust Sanger Institute, biomarker development linked to work at Karolinska Institutet, translational projects aligning with European Molecular Oncology Laboratory approaches, and clinical trial networks modelled on EORTC consortia. Specific scientific foci intersect with databases and registries like SEER Program-inspired national registries, biobanking efforts akin to BBMRI-ERIC, and precision oncology cohorts comparable to ICGC initiatives.
EURACAN partners with national cancer centres, academic hospitals, patient organisations, regulatory agencies, and industry consortia. Notable collaborative patterns include joint activities with European Commission Directorate-General for Health and Food Safety, research collaborations with Institut Pasteur, Max Planck Society, and CNIO (Spanish National Cancer Research Centre), and programmatic links to multinational trial consortia such as SIOP Europe and EACR. It works with patient advocacy groups like CANCER52 and LIVESTRONG Foundation-style national charities, and engages with professional societies including American Society of Clinical Oncology for guidelines harmonisation and UICC for global advocacy.
EURACAN’s funding model draws on European Commission grants under Connecting Europe Facility and Horizon Europe, national health ministry contributions from member states, project grants from agencies like European Research Council and European Innovation Council, charitable support from foundations such as Bill & Melinda Gates Foundation-style philanthropic partners, and restricted research funding from industry collaborators including multinational pharmaceutical companies active in oncology like Roche, Novartis, Pfizer, and AstraZeneca. Financial oversight employs accountability mechanisms similar to European Court of Auditors guidelines and compliance with GDPR for data governance.
EURACAN has influenced harmonisation of diagnostic criteria and referral pathways akin to standards promoted by NICE and HAS, contributed to multicentre trials with partners like EORTC and ESMO, and advanced registry-based research comparable to outputs from European Network of Cancer Registries. Outcomes include improved access to expert second opinions through platforms modeled on the Clinical Patient Management System, expanded biobanking aligned with BBMRI-ERIC standards, and policy impact via contributions to European Commission consultations and strategy documents adopted by member state ministries. Peer-reviewed outputs have appeared in journals commonly used by collaborators such as The Lancet Oncology, Journal of Clinical Oncology, and European Journal of Cancer.